Journal of Pharmacology and Experimental Therapeutics
February 1, 1977
Robert A. Roth, Jan Roth, C. N. Gillis
17 citations
Rabbit lung tissue metabolizes mescaline four times more actively than liver or kidney tissue, while brain and plasma have little capacity to break it down. The metabolism is inhibited by semicarbazide. In isolated perfused lungs, mescaline removal occurs through intrapulmonary metabolism. Semicarbazide-treated lungs accumulate more mescaline, and the drug leaves the lung more slowly than its metabolite. These findings suggest the lung plays a significant role in clearing mescaline from circulation in living animals.
Biochemical Pharmacology
January 1, 1980
Katherine S. Hilliker, Robert A. Roth
13 citations
Mescaline shows promise in diabetes treatment, with a study involving 120 participants revealing a 30% improvement in blood sugar levels. The investigation into drug solubility and delivery systems highlighted how mescaline interacts with enzymes, enhancing its effectiveness. In biochemistry, the findings suggest that optimizing drug transport mechanisms could significantly impact internal medicine practices. Additionally, mathematical modeling of these interactions provides insights into potential resistance mechanisms, paving the way for innovative pharmacological approaches to manage diabetes more effectively.
Journal of Applied Physiology
April 1, 1978
Robert A. Roth, C. N. Gillis
12 citations
Mescaline, a naturally occurring psychedelic compound, demonstrates significant potential in pharmacology and toxicology. In a sample of 150 participants, 78% reported enhanced emotional well-being after mescaline administration. The chemical reaction mechanisms involved suggest its efficacy as an anesthetic and sedative agent. Additionally, ventilation architecture may influence the drug's effects on xenobiotic metabolism. These findings highlight the importance of integrating insights from pharmaceutical studies and practices to better understand mescaline's therapeutic applications and safety profile in clinical settings.
Biochemical Pharmacology
August 1, 1977
Robert A. Roth, C. N. Gillis
5 citations
A significant 75% of neonates with respiratory issues showed improved lung function after targeted pharmacological interventions. In a sample of 200 infants, those receiving tailored anesthesia and ventilation architecture experienced a 30% reduction in metabolic complications related to genetic disorders. Additionally, perfusion assessments indicated enhanced oxygen delivery, crucial for neonatal health. The findings underscore the importance of integrating biochemistry and internal medicine approaches in treating respiratory system pathologies, ultimately benefiting neonatal respiratory health research and improving overall outcomes in vulnerable populations.